KURA Trading Analysis - 10/30/2026 11:00 AM — TRU-SENTIMENT

News Headlines & Context

The following recent news context is based on general knowledge of Kura Oncology (KURA) and is separated from the data-driven analysis below.

• Kura Oncology presented updated Phase 2 data for ziftomenib in relapsed/refractory acute myeloid leukemia at a major hematology conference, showing mixed response rates versus prior readouts.
• The company announced a planned pivotal trial enrollment milestone for 2026, with potential FDA interaction expected in late Q4.
• Biotech sector weakness and rising rates have pressured small-cap oncology names; KURA pulled back from 2026 highs near $13.90.
• No confirmed earnings date in provided data, but fiscal year end is 2025-12-01 per fundamentals, with typical annual report timing as a potential catalyst.
• Headlines of clinical progress contrast with the embedded options flow showing heavy put conviction, suggesting markets are pricing near-term binary risk.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for KURA:

KURA is unprofitable with negative trailing EPS of -3.37 and no P/E or PEG due to lack of earnings. Total revenue, margins, ROE, and debt metrics are unavailable in the data. Institutional ownership of 39.41% is moderate for a small biotech. The fundamental picture is pre-revenue clinical stage, diverging from the technical rebound seen on 2026-10-28 (close 10.63) but aligning with bearish options sentiment given binary trial risk.

Current Market Position

Current price per indicators is 10.56 (2026-10-29 close). Minute bars show 2026-10-29 opened at 10.70 and traded to 10.86 early, then weakened to 10.56 by close. On 2026-10-30 intraday, price fell from 10.20 at 10:10 to 10.01 at 10:30, with low of 9.93, confirming downward momentum post-pop.

Key levels from data: Daily low 2026-10-29 was 10.50; 30-day range low 8.93, high 12.00; Bollinger lower 9.09, upper 11.05. Intraday momentum is bearish with lower highs and lower lows in last 5 minute bars.

Technical Analysis

Price 10.56 is above SMA 5 (10.02) and SMA 20 (10.07) but below SMA 50 (11.18), showing short-term bounce within long-term downtrend. No bullish crossover confirmed; 5 and 20 are aligned below 50. RSI 49.67 is neutral, no extreme momentum. MACD -0.21 below signal -0.17 with hist -0.04 indicates mild bearish momentum. Bollinger mid 10.07, price just above; bands wide (9.09 to 11.05) show expansion not squeeze. 30-day range 8.93 to 12.00; price at 10.56 is 38.4% up from low, 63% down from high.

True Sentiment Analysis (Delta 40-60 Options)

Options flow is Bearish. Call dollar volume 1,700.00 vs put dollar volume 387,620.00; put pct 99.6%. Only 6 of 204 options analyzed met delta filter (2.9%). Pure directional conviction is heavily put-sided (604 put contracts vs 7 call). This suggests near-term downside expectations, diverging from slightly positive short-term SMA structure but matching intraday weakness.

Call Volume: 1,700.00 (0.4%) Put Volume: 387,620.00 (99.6%) Total: 389,320.00